Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F; AIDS Clinical Trials Group (ACTG).

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):193-200.

2.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
3.

[The "induction-maintenance" strategy].

Arribas López JR.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 16:8-11. Review. Spanish.

PMID:
19572438
4.

[Lopinavir/ritonavir in new initial antiretroviral treatment strategies].

Rolón MJ, Figueroa MI, Sued O, Cahn P.

Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:7-11. doi: 10.1016/S0213-005X(14)70161-2. Review. Spanish.

PMID:
25542869
5.

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.

Baril JG, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, Walmsley S.

PLoS One. 2016 Feb 5;11(2):e0148231. doi: 10.1371/journal.pone.0148231. eCollection 2016. Review.

6.

Pathogenesis and management of lipoatrophy.

Tungsiripat M, McComsey G.

Curr HIV/AIDS Rep. 2008 May;5(2):55-63. Review.

PMID:
18510890
7.

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.

Nelson M, Hill A, van Delft Y, Moecklinghoff C.

AIDS Res Treat. 2014;2014:636584. doi: 10.1155/2014/636584. Epub 2014 Feb 25. Review.

Supplemental Content

Support Center